Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 10/20 | 0.62 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.62 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | FAP | Q12884 | 1/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | HRH2 | P25021 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CHKA | P35790 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3331450 | 1.00 | DPP4 (0.62) | DPP4DPP8DPP9HPGDFAP | |
| SCHEMBL14548972 | 1.00 | DPP4 (0.62) | DPP4DPP8DPP9HPGDFAP | |
| SCHEMBL10326191 | 1.00 | DPP4 (0.62) | DPP4DPP8DPP9HPGDFAP | |
| SCHEMBL1383434 | 0.98 | DPP4 (0.64) | DPP4DPP8DPP9HPGDFAP | |
| SCHEMBL488954 | 0.98 | DPP4 (0.64) | DPP4DPP8DPP9HPGDFAP | |
| SCHEMBL488953 | 0.98 | DPP4 (0.64) | DPP4DPP8DPP9HPGDFAP | |
| Hydrochloric Acid SCHEMBL5413834 | 0.96 | DPP4 (0.62) | DPP4DPP8DPP9HPGDFAP | |
| SCHEMBL13661462 | 0.94 | DPP4 (0.56) | DPP4DPP8DPP9HPGDFAP | |
| SCHEMBL1871830 | 0.94 | DPP4 (0.56) | DPP4DPP8DPP9HPGDFAP | |
| SCHEMBL3332858 | 0.94 | DPP4 (0.64) | DPP4DPP8DPP9HPGDFAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105399698-B | Aromatic heterocyclic derivatives and its application in drug | 广东东阳光药业有限公司 | 2018-08-10 | — | — | CN | disclosed |
| EP-2438989-B1 | USE OF ASYMMETRIC HYDROGENATION CATALYST | TAKASAGO PERFUMERY CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-8669266-B2 | Quinoline-carboxamide derivatives as P2Y12 antagonists | SANOFI (FR) | 2014-03-11 | — | — | US | disclosed |
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-2148871-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008128647-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | WO | disclosed |
| US-20070249682-A1 | Novel CD40:CD154 binding interruptor compounds and use thereof to treat immunological complications | ZHENG ZHONGLI | 2007-10-25 | — | — | US | disclosed |
| US-20070249682-A1 | Novel CD40:CD154 binding interruptor compounds and use thereof to treat immunological complications | ZHENG ZHONGLI | 2007-10-25 | — | — | US | disclosed |
| US-7173046-B2 | CD40:CD154 binding interrupter compounds and use thereof to treat immunological complications | BIOGEN, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173046-B2 | CD40:CD154 binding interrupter compounds and use thereof to treat immunological complications | BIOGEN, INC. (US) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249682-A1 | Novel CD40:CD154 binding interruptor compounds and use thereof to treat immunological complications | CD40, CD40LG, TNFSF11 | DPP4 341/4885DPP8 777/4885DPP9 1030/4885 |
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | P2RY12, P2RY1, P2RY2 | DPP4 2699/4885DPP8 2973/4885DPP9 2264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.